A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3375880 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
Price : $35 *
At a glance
- Drugs LY 3375880 (Primary) ; LY 3375880 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 1 Nov 2018 to 19 Nov 2018.
- 23 Aug 2018 Planned primary completion date changed from 1 Nov 2018 to 19 Nov 2018.